NASDAQ:INO Inovio Pharmaceuticals (INO) Stock Price, News & Analysis $1.21 -0.04 (-3.20%) Closing price 04:00 PM EasternExtended Trading$1.20 -0.01 (-0.83%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Inovio Pharmaceuticals Stock (NASDAQ:INO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Inovio Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.18▼$1.2650-Day Range$0.66▼$1.4352-Week Range$0.56▼$2.72Volume2.83 million shsAverage Volume2.60 million shsMarket Capitalization$125.11 millionP/E RatioN/ADividend YieldN/APrice Target$3.17Consensus RatingModerate Buy Company Overview Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing DNA medicines designed to treat and prevent serious diseases. Its platform uses synthetic DNA plasmids to instruct cells to produce targeted proteins, with delivery supported by its CELLECTRA electroporation devices. The company’s research has included candidates for cancer, infectious diseases and human papillomavirus (HPV)-related conditions. Inovio’s pipeline has included INO-3107, an investigational DNA immunotherapy for recurrent respiratory papillomatosis, a rare disease caused by HPV, as well as other development programs targeting cancers and infectious diseases. These products remain subject to clinical testing and regulatory review, and the company has not established them as broadly approved treatments. Founded in the 1980s and formerly known as Inovio Biomedical, the company is headquartered in Plymouth Meeting, Pennsylvania. Inovio conducts clinical and development activities through collaborations and research programs that have extended across multiple geographic regions. Dr. Jacqueline Sha serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Inovio Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreINO MarketRank™: Inovio Pharmaceuticals scored higher than 60% of companies evaluated by MarketBeat, and ranked 325th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingInovio Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialInovio Pharmaceuticals has a consensus price target of $3.17, representing about 165.0% upside from its current price of $1.20.Amount of Analyst CoverageInovio Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Inovio Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Inovio Pharmaceuticals are expected to grow in the coming year, from ($0.72) to ($0.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inovio Pharmaceuticals is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inovio Pharmaceuticals is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInovio Pharmaceuticals has a P/B Ratio of 3.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Inovio Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.94% of the float of Inovio Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverInovio Pharmaceuticals has a short interest ratio ("days to cover") of 4.36.Change versus previous monthShort interest in Inovio Pharmaceuticals has recently decreased by 3.56%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInovio Pharmaceuticals does not currently pay a dividend.Dividend GrowthInovio Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.23 News SentimentInovio Pharmaceuticals has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Inovio Pharmaceuticals this week, compared to 7 articles on an average week.Search Interest15 people have searched for INO on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows7 people have added Inovio Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Inovio Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders1.70% of the stock of Inovio Pharmaceuticals is held by insiders.Percentage Held by Institutions26.79% of the stock of Inovio Pharmaceuticals is held by institutions.Read more about Inovio Pharmaceuticals' insider trading history. Receive INO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INO Stock News HeadlinesCan PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?2 hours ago | finance.yahoo.comInovio Pharmaceuticals (NASDAQ:INO) Stock Price Crosses Above 200-Day Moving Average - Here's What HappenedSeptember 19, 2026 | americanbankingnews.comBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25.September 24 at 1:00 AM | Paradigm Press (Ad)Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?September 14, 2026 | finance.yahoo.comInovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks TranscriptSeptember 11, 2026 | seekingalpha.comCan Papzimeos Drive Precigen's Growth Through the Rest of 2026?September 10, 2026 | finance.yahoo.comInovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference TranscriptSeptember 9, 2026 | seekingalpha.comINOVIO to Participate in Upcoming Investor ConferencesSeptember 1, 2026 | finance.yahoo.comSee More Headlines INO Stock Analysis - Frequently Asked Questions How have INO shares performed this year? Inovio Pharmaceuticals' stock was trading at $1.74 on January 1st, 2026. Since then, INO shares have decreased by 31.3% and is now trading at $1.1950. How were Inovio Pharmaceuticals' earnings last quarter? Inovio Pharmaceuticals, Inc. (NASDAQ:INO) issued its quarterly earnings data on Wednesday, August, 12th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.15. Read the conference call transcript. When did Inovio Pharmaceuticals' stock split? Inovio Pharmaceuticals's stock reverse split on the morning of Thursday, January 25th 2024.The 1-12 reverse split was announced on Thursday, January 25th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. Who are Inovio Pharmaceuticals' major shareholders? Top institutional investors of Inovio Pharmaceuticals include BlackRock Inc. (22.74%), Two Seas Capital LP (4.23%), Bank of New York Mellon Corp (0.90%) and Bank of America Corp DE (0.61%). View institutional ownership trends. How do I buy shares of Inovio Pharmaceuticals? Shares of INO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Inovio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inovio Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Moderna (MRNA), Novavax (NVAX) and Pfizer (PFE). Company Calendar Last Earnings8/12/2026Today9/24/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 INO's financial health is in the Green zone, according to TradeSmith. INO has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:INO CIK1055726 Webwww.inovio.com Phone(858) 410-3134Fax267-440-4242Employees112Year Founded1979Price Target and Rating Average Price Target for Inovio Pharmaceuticals$3.17 High Price Target$4.00 Low Price Target$2.50 Potential Upside/Downside+162.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$84.95 million Net MarginsN/A Pretax Margin-130,000.15% Return on Equity-669.94% Return on Assets-73.97% Debt Debt-to-Equity RatioN/A Current Ratio1.00 Quick Ratio1.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.36 per share Price / Book3.35Miscellaneous Outstanding Shares103,398,000Free Float101,640,000Market Cap$124.59 million OptionableOptionable Beta1.63 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:INO) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...American Alternative | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredArizona Gold Explorer Nears First-Ever Resource EstimateA little-known Arizona gold explorer just hit 66.2 metres grading 6.57 g/t gold, including 20.7 metres at 18.2...Wall Street Logic | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inovio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inovio Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
